I reported previously (see here) on Israeli biotech Ayala and its personalized cancer treatment. It is already partnering with Bristol-Myers Squibb. Now multinational Novartis has made a $|10 million investment in Ayala, focusing on the aggressive blood cancer multiple myeloma. … Continue reading →

I wrote previously (10th Dec) about Israeli personalized cancer biotech Ayala and its partnership with Bristol-Myers Squibb. One of the results of this tie-up is AL101 – a new treatment for metastatic Adenoid Cystic Carcinoma (ACC), which could also treat … Continue reading →

I reported previously (many times) on Israeli companies developing cancer treatments targeting individuals rather than specific areas of the body. Now, Israeli biotech Ayala is partnering with Bristol-Myers Squibb to develop treatments for cancer patients known to have a gene … Continue reading →